Uptravi (Selexipag) Patent Expiration, LOE Window & CMS Spending

Uptravi (Selexipag) by Johnson & Johnson: FDA Orange Book core substance LOE 2031-02-01 (last listed 2037-06-01), 2 AB generics, $287.5M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorJohnson & Johnson
FDA Application & PathwayN207947 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2031-02-01
Last Listed Patent or Exclusivity Date2037-06-01
Orange Book Patents (*PED Extensions)12 patents (6 *PED)
Active AB-Rated Generic Competitors2
2024 CMS Total Public Spend$287.5M
2024 Medicare Part D Spend$0
2024 Medicaid Spend$287.5M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Johnson & Johnson across sibling Meru public-data platforms.